Testosterone Therapy in HIV-Infected Men: Suboptimal Testing for Diagnosis and Monitoring

Publish Date: 
Monday, April 20, 2015

Very few data are available to gauge the possible benefits and adverse effects of long-term testosterone supplementation in HIV-infected men. Despite this, and despite concerns about possible risks of testosterone supplementation (eg, cardiovascular events, prostate cancer), testosterone continues to be widely prescribed for both HIV-infected and HIV-uninfected men in the United States.

Using Fellowships to Impact HIV Workforce Deficits

Publish Date: 
Wednesday, April 1, 2015

A critical shortage of practitioners who treat HIV/AIDS patients in the United States is on the horizon, according to research by the American Academy of HIV Medicine (AAHIVM), which warns that more than 32 percent of today’s HIV clinicians will stop providing that care over the next 10 years. Nearly one-third of today’s workforce will retire leaving a shortage unless new practitioners can be encouraged to replace them.

Two New Boosted-PI Coformulations

Publish Date: 
Tuesday, March 17, 2015
The coformulations will make it possible to treat patients with more compact PI-based regimens, (and single-pill combinations containing these boosted PIs + 2 NRTIs may be available in the future). Adverse effects to cobicistat appear to be very similar to those associated with ritonavir, and drug-drug interactions also are about the same.

Drug-Drug Interactions: Tenofovir with Boosted PI + Ledipasvir

Publish Date: 
Tuesday, March 17, 2015

It has been reported that the hepatitis C combination medication ledipasvir/sofosbuvir (LDV/SOF, Harvoni), and in particular the ledipasvir component, may increase tenofovir levels in the body. It also is known from previous investigations that ritonavir-boosted protease inhibitors (PIs) increase serum tenofovir concentrations. Thus, there has been a concern that coadministration of tenofovir with both ledipasvir and a boosted PI may increase the risk of renal toxicity.

Tenofovir-Containing ART as HBV Prophylaxis

Publish Date: 
Tuesday, March 17, 2015
Use of tenofovir as part of the ART regimen was associated with a sharply lower rate of HBV infection,

Switch to TDF/FTC from ABC/3TC Lowers Lipids

Publish Date: 
Tuesday, March 17, 2015
At week 12, all lipid measures had decreased in the switch group but not in the control group: total cholesterol dropped 33 mg/dL, LDL and triglycerides dropped 17-18 mg/dL, and HDL dropped 6 mg/dL. At week 24, similar changes were seen in the remaining patients switched to TDF/FTC. Authors report no changes in eGFR and no differences between groups in rates of proteinuria.

Bug Chasers: Gay Men and the Intentional Pursuit of HIV - A Narrative Analysis

Publish Date: 
Wednesday, February 4, 2015

Imagine you are sitting down with a dear friend that you haven’t seen in years because he ran away from an unloving, unsupportive home, from a town where he was different, picked on, and knew he could never be safe - at least that is how he felt, - to a place where he would find love, and the supportive family he so dearly wanted. He discloses that he is gay and living with HIV infection.  He says not to worry, that it’s ok, and then he says, “There’s more.”  You feel your heart beat faster and time suspends.

Pages

Subscribe to Sharespot RSS feed